Latest Hydrix (ASX:HYD) News

Takeovers, mine studies and record quarterly updates drove the week, with buyers chasing companies that put hard numbers around cash flow, reserves and contract wins. Losses were just as sharp where traders sold into reopenings or questioned whether fresh capital and non-binding deals would turn into profits.

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.

Hydrix has landed a A$3.4 million contract with US-based Remedy Robotics to develop safety-critical software and embedded electronics for the N1 robotic system, marking a major step in its medical robotics ambitions.

Space batteries, telecom AI and a healthcare software leadership change drove the week’s biggest moves in small-cap tech. Capital raisings and debt deals also shaped trading, with several early jumps fading as investors weighed dilution and execution risk.

Hydrix Limited has secured $5.22 million from its retail entitlement offer, leaving nearly $3 million in entitlements unsold, which will be offered separately under a shortfall offer managed by Peak Asset Management.

Capital raisings drove the week in ASX tech, with investors backing AI and data centre spending but punishing deep discounts. The biggest moves came from small-cap fundraisings, while AI infrastructure names drew the clearest buying support.

Hydrix Limited has closed the retail component of its $8.18 million entitlement offer, raising $1.34 million through a 31% participation rate. The company aims to use the proceeds to reduce debt, support operations, and invest in defence technology, with a significant convertible note debt conversion pending shareholder approval.

Tiny tech stocks dominated the tape, with Thrive Tribe, Harvest Technology and Bridge SaaS posting the biggest weekly jumps. Capital raisings, AI product launches and defence-linked deals drove buying, while heavily discounted offers and fraud concerns hit the losers.

Hydrix Limited has launched the retail phase of its accelerated entitlement offer aiming to raise up to $8.18 million by issuing six new shares per existing share at $0.005 each, plus free options. The institutional component has closed, and retail shareholders have until 5 June to participate.

Capital moves, contract wins and AI product pushes drove a busy week across small and mid-cap technology stocks. Hydrix, Complii and ClearVue led the board, while investors sold names where early excitement gave way to dilution concerns or softer earnings detail.

Hydrix Limited has bolstered its balance sheet by raising $3.89 million and converting $5.1 million of debt into equity, positioning itself to expand its Defence technology footprint following a $1.2 million contract with NIOA Group.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.